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Abstract
Background
HIV-1 and Plasmodium falciparummalaria cause substantial morbidity in Sub-Saharan Af-
rica, especially as co-infecting pathogens. We examined the relationship between presence
of P. falciparum DNA in plasma samples and clinical malaria as well as the impact of ataza-
navir, an HIV-1 protease inhibitor (PI), on P. falciparum PCR positivity.
Methods
ACTG study A5175 compared two NNRTI-based regimens and one PI-based anti-retroviral
(ARV) regimen in antiretroviral therapy naïve participants. We performed nested PCR on
plasma samples for the P. falciparum 18s rRNA gene to detect the presence of malaria
DNA in 215 of the 221 participants enrolled in Blantyre and Lilongwe, Malawi. We also stud-
ied the closest sample preceding the first malaria diagnosis from 102 persons with clinical
malaria and randomly selected follow up samples from 88 persons without clinical malaria.
Results
PCR positivity was observed in 18 (8%) baseline samples and was not significantly as-
sociated with age, sex, screening CD4+ T-cell count, baseline HIV-1 RNA level or co-tri-
moxazole use within the first 8 weeks. Neither baseline PCR positivity (p = 0.45) nor PCR
positivity after initiation of antiretroviral therapy (p = 1.0) were significantly associated with
subsequent clinical malaria. Randomization to the PI versus NNRTI ARV regimens was not
significantly associated with either PCR positivity (p = 0.5) or clinical malaria (p = 0.609).
Clinical malaria was associated with a history of tuberculosis (p = 0.006) and a lower BMI
(p = 0.004).
PLOS ONE | DOI:10.1371/journal.pone.0129519 June 8, 2015 1 / 11
OPEN ACCESS
Citation: Orlov M, Smeaton LM, Kumwenda J,
Hosseinipour MC, Campbell TB, Schooley RT (2015)
Presence of Plasmodium falciparum DNA in Plasma
Does Not Predict Clinical Malaria in an HIV-1 Infected
Population. PLoS ONE 10(6): e0129519.
doi:10.1371/journal.pone.0129519
Academic Editor: Cheryl A. Stoddart, University of
California, San Francisco, UNITED STATES
Received: December 21, 2014
Accepted: May 8, 2015
Published: June 8, 2015
Copyright: © 2015 Orlov et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The authors do not
own the data underlying this paper. Data are available
for specific analyses upon electronic request to the
NIAID’s AIDS Clinical Trials Group (https://
actgnetwork.org/clinical-trials/access-published-data).
Funding: This work was supported in part by NIH
Grants 1U01AI068636, 1U01AI068634,
1U01AI069432 and 1U01AI069423 and by
unrestricted funds from the UCSD Division of
Infectious Diseases. Dr. Schooley has utilized
compensation for consultative services for Gilead
Sciences that were paid to UCSD to support Dr.
Conclusion
P. falciparum DNA was detected in 8% of participants at baseline, but was not significantly
associated with subsequent development of clinical malaria. HIV PI therapy did not de-
crease the prevalence of PCR positivity or incidence of clinical disease.
Introduction
HIV-1 and Plasmodium falciparummalaria are two of Sub-Saharan Africa’s major contributors
to morbidity and mortality. Although the interaction between the two diseases was initially dis-
missed [1,2], more contemporary data support a bi-directionally deleterious interaction [3–7].
Although the majority of deaths from malaria are in children under 5 years of age, pregnant
women and immunocompromised individuals (including those with HIV-1 infection) are also
at increased risk for poor outcomes [8]. Adaptive immune responses developed during repeti-
tive malaria episodes protect individuals from severe disease, however sterilizing immunity to
P. falciparum infection never fully develops as individuals remain susceptible to both clinical
disease and asymptomatic infections [9]. This asymptomatic carrier state has been termed sub-
clinical (if the parasites are detectable in a blood smear) or subpatent (if the parasites are de-
tectable by more sensitive methods such as PCR) parasitemia. While some studies suggest that
subclinical and subpatent parasitemias are associated with the development of partial immuni-
ty and confer protection against future development of clinical disease [10,11], others suggest
that the presence of asymptomatic parasitemia could itself be a marker for the development of
clinical disease[12]. Very few such studies have been conducted in HIV infected populations
[13,14].
HIV protease inhibitors (PIs) are in wide use for treatment of HIV infection in the US and
Europe, but in resource limited settings, PIs are primarily reserved for second-line therapy. Al-
though PIs inhibit replication of P. falciparum in tissue culture [15], their influence on the par-
asite in vivo has not yet been fully delineated. In one recently completed adult clinical trial
comparing nevirapine-based (NNRTI) treatment to ritonavir-boosted lopinavir-based (PI)
treatment, lopinavir therapy was not associated with lower rates of malarial antigen detection
or clinical disease [16,17]. However a recently published trial in children showed a substantial
decrease in clinical malaria incidence in the PI treated group [18]. In this study the reduction
in malaria in the PI arm was observed only in the second and subsequent bouts of malaria and
suggested that the overall reduction was driven primarily by increases in anti-malarial drug ex-
posure caused by drug-drug interactions between PI’s and anti-malarial drugs used to treat the
initial bouts of malaria in these children.
In the present study, we used a highly sensitive nested polymerase chain reaction (nPCR) to
determine whether subpatent parasitemia was a predictor of clinical malaria and if treatment
with atazanavir was associated with lower rates of subpatent parasitemia or clinical disease in
study participants recruited to a clinical trial of antiretroviral therapy that was conducted in
Malawi.
Methods
IRB approval and informed consent were obtained from all participants in the parent study
(see reference below). The UCSD Human Research Protections Program approved the use of
the already collected patient samples in the ACTG study for this study.
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Patient population and sampling
PEARLS (Prospective Evaluation of Antiretrovirals in Resource limited settings, also known as
ACTG A5175) randomized treatment-naïve individuals with CD4+ T-cells/mm3 counts
of< 300 to lamivudine/zidovudine plus efavirenz, emtricitabine/tenofovir-DF plus efavirenz,
or didanosine plus emtricitabine plus atazanavir (not ritonavir boosted) [19]. PEARLS re-
cruited 1571 participants in 9 countries and included sites in Blantyre and Lilongwe, Malawi.
During a median follow up period of three years, all but one of the 245 bouts of clinical malaria
in the trial occurred in the 221 study participants recruited by the two sites in Malawi. We thus
concentrated our evaluation of subpatent P. falciparum parasitemia on Malawian study enroll-
ees. Cases of malaria were prospectively defined as ‘confirmed’ when study participants pre-
sented for clinical care with a compatible clinical syndrome (as determined by the individual
investigator at each site) and were found to have Plasmodium sp. parasites on a peripheral
blood smear and as ‘probable’ when study participants presented with a compatible clinical
syndrome and specific treatment for P. falciparum was initiated or recommended without lab-
oratory confirmation by a positive blood smear.
Plasma samples were obtained prior to study entry and at regular intervals during follow-up
based on the sampling schedule dictated by the clinical trial. The sampling strategy for the eval-
uation of P. falciparum parasitemia is illustrated schematically in Fig 1. Of the available plasma
samples collected during the antiretroviral chemotherapy study (all arrows), we selected a sub-
set for analysis for the presence of P. falciparum DNA (subpatent parasitemia, orange arrows).
Baseline samples were defined as those obtained prior to the initiation of antiretroviral therapy
(N = 113) or within 8 weeks following entry into the clinical trial (N = 102). Two participants
were removed from the analysis because they had active malaria at entry into the ARV study.
Among the 18 study participants with positive baseline samples, another sample obtained 4–12
weeks later was requested to test for persistence of subpatent parasitemia. For the 122 partici-
pants who had a clinical malaria diagnosis during the study, PCR testing for subpatent parasi-
temia was also performed on the closest available specimen prior to the first diagnosis of
clinical malaria. These samples were drawn an average of 31 days (range 1–60 days) prior to
the malaria diagnosis. For those who never had a clinical malaria diagnosis (controls, 88), a
2-stage restricted sampling design was used to control for 2 potential confounding factors: time
of year (high malaria season [November through May] versus low [remainder of year]) and ex-
posure time to ARVs. Time since ARV initiation was divided into four intervals:<12 weeks,
Fig 1. Schematic Diagram of Sampling Strategy.Of all the plasma samples that were collected for the PEARL study (all arrows), we used a subset of
those samples for our study (orange arrows). We assayed all available baseline samples which were collected at entry into the antiretroviral study (215), the
closest sample banked prior to a malaria episode (102), and control plasma samples from participants that did not develop malaria matched for time of year of
sampling and length of time on antiretroviral therapy (88).
doi:10.1371/journal.pone.0129519.g001
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12–24 weeks, 24 -< 96 weeks, and 96+ weeks. “Early” co-trimoxazole use refers to administra-
tion in the first 8 weeks of study.
DNA extraction and PCR
200μL of plasma were used to extract DNA using Qiagen Mini Blood Kit (Qiagen) as per man-
ufacturer’s instructions. The nested PCR (nPCR) for P. falciparum detects a 205bp portion of
the 18s rRNA gene. A nested PCR reaction was performed on 40μL of supernatant from the ex-
traction in a 50μL PCR reaction (2.5 U Taq polymerase (Invitrogen), 3mMMgCl2, 500nM
dNTPs (Fermentas), and 50 pmol of each primer (IDT). In the first round of the nPCR, the
gene was amplified using primers fPLU: 5’-TTA AAA TTG TTG CAG TTA AAA CG-3’, and
rPLU: 5’-CCT GTT GTT GCC TTA AAC TTC-3’. Denaturation was performed at 94°C for
3 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 58°C for
1 minute, and elongation at 72°C for 2 minutes, with a final extension at 72°C for 5 minutes.
2μL of the outer PCR product was used as the template for the inner PCR reaction (50μL total)
using primers fFAL: 5’-TTAAACTGGTTTGGGAAAACCAAATATATT-3’ and rFAL: 5’-
ACACAATGAACTCAATCATGACTACCCGTC-3’. For the inner PCR, denaturation was
performed at 94°C for 3 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds,
annealing at 58°C for 1 minute, and elongation at 72°C for 1 minute, with a final extension at
72°C for 5 minutes. The PCR products from the inner PCR were run on a 1% agarose gel
(175V, 30 minutes) and stained with ethidium bromide. The PCR result was qualitative and
could detect parasite DNA in the plasma down to 1.8 parasite genomes/5μL of extracted DNA.
The sensitivity threshold was defined by performing serial dilutions starting from a known
parasitemia, followed by DNA extraction and then PCR.
Statistical Analysis
Categorical variables were compared by Fisher’s exact test and continuous variables were com-
pared with Wilcoxon Rank-Sum Test. Univariable logistic regression examined the association
between subpatent parasitemia at baseline (or during follow-up) and clinical malaria diagnosis
during study follow-up. To control for confounders, effect modifiers, and other prognostic fac-
tors, multi-variable logistic regression was used including covariates identified as associated
with either development of clinical malaria during follow-up, or with subpatent status. Adding
subpatent status tested for independent association provided by a plasma DNA finding at base-
line. Since all of the participants placed on atazanavir were switched to NNRTI therapy after a
median of 102 weeks in the trial and some participants were crossed over from NNRTIs to PIs
or vice versa due to HIV outcome failures over the course of the study, the effect of PI therapy
on subpatent parasitemia and clinical malaria outcomes were investigated using an as-treated
analysis. Because we did not see any effect of drug therapy on subpatent parasitemia or clinical
malaria outcomes, an intent-to-treat analysis was used for the remainder of our analysis.
Results
Subpatent Parasitemia
Of the 219 participants analyzed, 147 (67%) were female and 72 (33%) were male and the
mean age was 33 (range 18–65). PCR positivity was observed in 18 (8.4%, 95% CI 5.0 to 12.9%)
of 215 baseline samples. There was a trend toward a greater likelihood of PCR positivity in
those with a lower BMI (p = 0.114) and lower hemoglobin levels (p = 0.066). There was no
significant association between PCR positivity and early cotrimoxazole use, age, gender,
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CD4+ T-cell count or plasma HIV-1 RNA levels. None of the 37 participants with a prior tu-
berculosis diagnosis were found to have PCR positivity (p = 0.027) (Table 1).
Of the 219 participants, 56% (122) developed probable (28/122) or confirmed (94/122) clin-
ical malaria. Neither PCR positivity at baseline (p = 0.45) nor during follow-up visits (p = 1.0)
was associated with the subsequent development of confirmed or probable malaria over the
course of the study. 50% of those with PCR positivity at baseline had a bout of clinical malaria
within the first 24 weeks while 24% of those without PCR positivity at baseline had clinical ma-
laria in the same time period (positive predictive value of 50%, 95% CI: 26–74). The sensitivity
of PCR positivity for predicting clinical malaria in this interval was only 16% (95% CI: 8–23).
PCR positivity was detected in only 7 (6.9%) of the closest plasma samples collected prior to
the onset of the first bout of clinical malaria in 102 individuals during the trial. Among the 88
controls that were selected because they did not experience clinical malaria during the study,
PCR positivity was detected at the same frequency (6.8%) (Fig 2), further suggesting that sub-
patent parasitemia was not a useful predictor of clinical disease (p = 1.0) in this patient popula-
tion. Importantly, PCR positivity was not associated with length of time that had elapsed
between plasma collection and clinical diagnosis among those with a clinical malaria episode
(p = 0.6). Randomization to the atazanavir arm was not significantly associated with a decrease
in subpatent parasitemia compared to those assigned to the efavirenz arms (OR 1.23, 95% CI
0.46–3.33, p = 0.7). In samples that were tested after the initiation of ARV therapy, the preva-
lence of PCR positivity was relatively stable over the 3 year study (5–10%) (Fig 3).
Table 1. Correlates of Baseline Subpatent Malaria.
No Subpatent Parasitemia
(N = 197)
Subpatent Parasitemia
(N = 18)
OR* (95% CI; p-value)
Malaria Season of Sample High
(Rainy)
93 (86%) 12 (14%) 1.90 (0.72–5.03;
p = 0.189)
Low (Dry) 104 (95%) 6 (5%)
BMI Mean (s.d.) 22 (4) 21 (3) 0.88 (0.74–1.04;
p = 0.114)
Hemoglobin Value(g/dL) Mean (s.d.) 12 (2) 11.2 (1.7) 0.83(0.65–1.05;
p = 0.066)
Any History of TB No 160 (90%) 18 (10%) 0.11(0.01–1.92;
p = 0.027)
Yes 37 (100%) 0 (0%)
CD4+ Cell Count Mean (s.d.) 169 (79) 184 (66) 1.00(1–1.01; p = 0.298)
Plasma HIV-1 viral load(log10 copies/
mL)
Mean (s.d.) 5.0 (1) 5.0 (1) 0.76(0.40–1.43;
p = 0.406)
Age Mean (s.d.) 33 (8) 33 (8) 1.01(0.95–1.07;
p = 0.721)
Gender Male 64 (90%) 7 (10%) 0.65(0.25–1.70;
p = 0.386)
Female 133 (92%) 11 (8%)
Early TMP/SMX use Yes 24 (96%) 1 (4%) 1.20(0.45, 3.20;
p = 0.713)
No 173 (91%) 17 (9%)
Randomization to NNRTI arm NNRTI 130 (92%) 11 (8%) 0.70(0.27–1.82;
p = 0.466)
PI 67 (91%) 7 (9%)
*OR values are not adjusted.
doi:10.1371/journal.pone.0129519.t001
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PCR positivity persisted after the initiation of antiretroviral therapy. If a baseline sample
was PCR positive, we continued testing follow up samples from the same individual until they
were no longer positive. Of the 18 positive samples at baseline, a follow-up sample was available
for 17; 76% (13/17) of these samples remained positive (follow-up samples obtained 4–8 weeks
after baseline). Among the 13 remaining positive at the second determination, only 30% (4/13)
remained positive when a third sample collected 1–8 weeks later was tested. The patterns of
persistent PCR positivity were not associated with NNRTI use (p = 1.0) or early co-trimoxazole
use (p = 1.0). Persistent positivity was not associated with a diagnosis of clinical malaria over
the course of the trial (confirmed p = 0.3; probable and confirmed p = 0.8).
Clinical Malaria
A total of 122 of the 219 participants (56%) had at least one probable or confirmed malaria di-
agnosis during the course of the three-year study, for a total of 238 clinical events. Clinical ma-
laria (confirmed or probable) was observed more frequently in those with history of
tuberculosis (OR 2.91, 95% CI 1.30–6.52, p = 0.006) and with a lower body mass index (OR
0.89, 95% CI 0.82–0.97, p = 0.004). Those using cotrimoxazole in the first 8 weeks were more
likely to develop clinical malaria (OR 1.80, 95% CI 1.01–3.23, p = 0.045) but this association
did not persist once adjusted for baseline BMI and TB history. Other baseline characteristics
including CD4+ T-cell count, plasma HIV-1 RNA level and hemoglobin levels were not signifi-
cantly associated with development of clinical malaria during the study (Table 2). Confirmed
clinical malaria was only associated with baseline BMI (OR 0.89, 95% CI 0.82–0.97, p = 0.007).
Fig 2. Detection of Subpatent Parasitemia does not predict development of clinical disease. Subpatent parasitemia is not a good predictor of
development of clinical disease. Among the 102 cases of malaria for whom plasma was available for PCR preceding diagnosis, subpatent parasitemia was
detected in only 7 (6.9%). Among 88 controls without subsequent clinical malaria, 6 (6.8%) had subpatent parasitemia detected. Levels of subpatent
parasitemia were equivalent in the participants that went on to develop clinical disease to those that never developed clinical malaria over the course of
the study.
doi:10.1371/journal.pone.0129519.g002
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Finally, ARV regimen was not significantly associated with confirmed or probable clinical ma-
laria (OR = 1.16, 95% CI 0.66–2.04).
Discussion
Over the past decade, there has been substantial discussion and debate about the extent to
which P. falciparum co-infection influences the morbidity and mortality of HIV disease and
Fig 3. Prevalence of Subpatent Parasitemia Over the Course of the Study.We analyzed 215 baseline
plasma sample, the closest available plasma sample prior to the first malaria diagnosis for 102 participants,
and a stratified random sample from 88 study participants who never had a malaria diagnosis. PCR positivity
remained relatively stable (5–10%) over the course of the study in the samples that we assayed.
doi:10.1371/journal.pone.0129519.g003
Table 2. Correlates of Probable and Confirmed Clinical Malaria.
None (N = 97) Probable(N = 28) Confirmed(N = 94) OR*(95% CI; p-value)
BMI Mean (s.d.) 23 (4) 22 (3) 21 (3) 0.89(0.82–0.97; p = 0.004)
Screening CD4+ Cell Count Mean (s.d.) 168 (78) 169 (83) 173 (78) 1.00(1.0–1.0; p = 0.702)
Plasma HIV-1 viral load (log10 copies/mL) Mean (s.d.) 5 (1) 5 (1) 5 (1) 1.13(0.77–1.67; p = 0.532)
Early TMP/SMX use No 72 (49%) 17 (12%) 58 (39%) 1.80(1.01–3.23; p = 0.045)
Yes 25 (35%) 11 (15%) 36 (50%)
Any History of TB No 88 (48%) 22 (12%) 72 (40%) 2.91(1.30–6.52; p = 0.006)
Yes 9 (24%) 6 (16%) 22 (60%)
Hemoglobin Value(g/dL) Mean (s.d.) 12 (2.1) 11.8 (1.8) 11.9 (1.9) 0.97(0.84–1.11; p = 0.658)
Randomized Treatment Group NNRTI 66 (46%) 22 (15%) 57 (39%) 1.16(0.66–2.04; p = 0.609)
PI 31 (42%) 6 (8%) 37 (50%)
*OR values are not adjusted.
doi:10.1371/journal.pone.0129519.t002
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vice versa. As additional data have accumulated it appears that some of the contradictory find-
ings fueling this debate have been driven by the dynamic and complex interplay among these
two pathogens and the human immune system and are heavily influenced by the underlying
prevalence of each of the two pathogens in a given population [20,21]. We studied a population
of adults in a region hyperendemic for malaria immediately before and after initiating antire-
troviral therapy to better understand this interplay. At the time when the PEARLS trial was ini-
tiated in 2005, the districts of Blantyre and Lilongwe together had 23% of the total new malaria
cases in Malawi, with the number of malaria cases being 27% and 21% of the total percent of
the population, respectively [22]. The incidence of malaria cases was found to be higher in fe-
males and in individuals with HIV [22]. Given that our sub-study population was 67% female
and all of the participants had CD4+ T-cell counts less than 300/mm3, it is not surprising that
about half of the participants had documented clinical events and some of them had more than
1 event over the course of the trial. Our primary goal was to determine whether the detection
of P. falciparum DNA in plasma samples obtained from those with relatively advanced HIV-as-
sociated immunodeficiency was a predictor of clinical malaria or, alternatively, that PCR posi-
tivity in the absence of clinical disease identifies partially immune individuals who have the
capacity to immunologically control the organism.
In our study we found that PCR positivity was not significantly associated with subsequent
development of clinical malaria. Neither lower pre-entry CD4+ T-cell counts nor higher plas-
ma HIV-1 RNA levels at study entry were significantly associated with either PCR positivity or
clinical malaria. While other studies have documented an association between lower CD4+ T-
cell counts and increased episodes of malaria, these studies included patients with a relatively
wide range of CD4+ T-cell counts and ours was restricted to candidates for antiretroviral thera-
py and composed only of those with CD4+ T-cell counts below 300/mm3[23]. We did find that
presence of P. falciparum DNA in the plasma at study entry and development of clinical malar-
ia were more common in those with a lower BMI. PCR positivity at study entry was also more
common in those with lower hemoglobin levels and in those with no prior history of TB. In
contrast, development of probable or confirmed clinical malaria was positively associated with
a history of TB. Although these seemingly contradictory findings are driven by relatively small
numbers of patients, one could speculate that those without a prior history of tuberculosis were
more immunologically competent and, thus, able to maintain P. falciparum in a subpatent
state while those with a prior history of tuberculosis were more likely to develop clinical disease
when they were exposed to the parasite.
In addition, we did not observe an association between HIV protease inhibitor therapy and
PCR positivity or clinical malaria in our small study. Andrews, et al, demonstrated that several
PIs, including atazanavir, reach concentrations in the plasma that exceed the EC50 for anti-ma-
laria activity in vitro [24]. Sera from subjects taking PIs have been reported to have antimalarial
activity in vitro, supporting the possibility that PIs reach levels in the range required for anti-
malarial activity [25,26]. Atazanavir blood levels in the PEARLS study (28nM–14μM) [27]
overlapped those required to inhibit parasite growth in vitro (2.5–11.6 μM) [15], though ataza-
navir blood levels in some participants in the trial would have been lower than those required
to suppress malarial parasites in vitro. In a recently reported study of 745 HIV-infected African
women, ritonavir boosted lopinavir did not decrease the incidence of clinical malaria or subpa-
tent parasitemia (detected using a malaria rapid antigen test) [16,17]. In another study in
children, although PIs were not associated with a lower incidence of initial bouts of malaria,
subsequent bouts were delayed [18]. This reduction in clinical disease among those on HIV
protease inhibitors was attributed by the investigators to increased persistence of antimalarial
drugs following treatment of the initial bout of malaria which was driven by drug-drug interac-
tions between the protease inhibitors and the antimalarial drugs used in the study.
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In conclusion, detection of P. falciparum DNA in this population of HIV-1 infected adults
residing in a hyperendemic area for malaria was not significantly associated with subsequent
clinical disease. Our study has a number of important limitations. First, the study was retro-
spective using available samples from a previously completed antiretroviral drug study. Al-
though many cases of malaria were reported among the Malawi participants, plasma samples
were not routinely collected at the time of the malaria episode. The samples available were col-
lected at study entry and at regular intervals during the study for the purpose of assessing the
efficacy of antiretroviral therapy. Although we did not see an association between parasitemia
and the amount of time elapsed to subsequent diagnosis of clinical malaria, the samples were
collected, on average, 31 days prior to the malaria diagnosis. The low prevalence of baseline
and follow-up PCR positivity and clinical malaria cases limited the statistical power to detect
the effect of the PI-based therapy. Lastly, we had access to frozen plasma samples, not blood
spots. Although others have previously reported that parasite DNA can be found in the plasma
of patients with clinical malaria [28,29], the use of this approach to evaluate the prevalence of
subclinical or subpatent P. falciparum infection has not been previously reported. The quanti-
tative and qualitative relationships between levels of detection of P. falciparum DNA in blood
(or dried blood spots) compared to plasma have not been extensively studied. However, in one
study using quantitative PCR, parasite DNA was detected in blood in 3.5-fold more samples
than in plasma [30]. Although the comparison was complicated by the use of different primer/
probe sets for the detection of parasite DNA in the blood versus the plasma, it is biologically
probable that blood samples would be more sensitive than plasma samples for the detection of
plasmodium DNA. A similar comparison of the sensitivity of nested PCR has not yet been re-
ported. Nonetheless, the use of frozen plasma samples for studies of malarial prevalence could
open doors to the study of changes in prevalence of the parasite over time in archived samples
collected for other reasons–especially in the context of malaria eradication studies. Most of the
prior studies that have addressed the impact of P. falciparum infection on HIV-1 and vice versa
have been conducted using clinical evidence of malaria as a marker for P. falciparum. Larger
scale longitudinal studies of PCR positivity and of clinical disease in regions of varying malaria
endemnicity, in additional HIV-infected populations, are needed to more conclusively examine
the clinical implications of PCR positivity and of the impact of PCR positivity on the natural
history of HIV-1 infection. Finally such studies, when combined with more focused studies of
malaria-specific immunity, could provide important insights into the immunological correlates
of protective immunity.
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